RE:RE:RE:Leede Jones Gable Inc recommends ONC!!!From LeedeJonesGable report:
Oncolytics Biotech to present two abstracts at upcoming San Antonio Breast Cancer Symposium: The meeting is expected to take place from December 6th to December 10th, with the firm presenting its posters on December 7th . Further details on both posters will presumably be made available after the policy on embargo for the symposium is lifted. Presented below are our key takeaways from the available information, and with both updates centered on Oncolytics’ leading reovirus formulation Reolysin/pelareorep.
The first presentation will be an update on Phase I data from the firm’s Chinese partner Adlai Nortye’s (Private) single-arm bridging trial in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. Data is derived from the cut-off date in Jun/22, with 10 patients treated in the trial so far. At time of cut-off, 9 patients experienced response in the form of partial response (PR) or stable disease (SD). Specifically, 4 patients achieved a partial response (out of which 2 patients were confirmed for PR) while 5 patients demonstrated stable disease. Looking ahead, data from this bridging trial will be critical to accelerating Adlai Nortye’s clinical development plans for China, with future regulatory submissions potentially tying in data from this bridging trial and data from Oncolytics’ North American metastatic breast cancer trials (IND-213 and 48- patient BRACELET-1 testing pelareorep in combination with Pfizer’s [PFE-NY, NR] anti-PD-L1 mAb avelumab/Bavencio). Data readout from BRACELET-1 is expected by H123. In a separate poster-presentation, the firm will be presenting on gene expression analyses from its 38-patient AWARE-1 trial. Data on the trial was centered on the first two cohorts of patients with HR+/HER2- breast cancer subtype receiving treatment with pelareorep and letrozole, and with cohorts distinguished by the addition of Roche’s (ROG-SW, NR) PD-L1 checkpoint inhibitor atezolizumab (cohort 1 did not receive atezolizumab while cohort 2 did receive treatment in combination with atezolizumab.
Our key takeaway from this abstract is that the gene expression analyses provide support for pelareorep’s ability to work synergistically alongside atezolizumab by altering the tumor microenvironment in order to induce anti-tumor activity as conferred by the checkpoint inhibitor